You are here: Industry Insights > Merck

News List

Vaccine market expected to grow at a CAGR of 7.5% by 2022 pharmaasia
August 29, 2017
The vaccine market is forecast to reach US$49.27 billion by 2022 at a CAGR of 7.5% from US$34.30 billion in 2017.
Merck sees promise in Macrophage Pharma pharmatimes
August 25, 2017
Merck Ventures has become the latest group to invest in Macrophage Pharma and take a position on the UK biotech’s board of directors.
Sanofi files patent infringement suit against MSD in US pharmatimes
August 10, 2017
Sanofi says that it has filed a patent infringement suit against Merck Sharp & Dohme in the United States District Court for the District of New Jersey, alleging the infringement of two patents.
Merck and GlaxoSmithKline production issues lead to global shortage of hepatitis B vaccine fiercepharma
August 10, 2017
A global shortage of vaccine to fight the hepatitis B virus had developed as both Merck & Co., and GlaxoSmithKline deal with manufacturing issues.
Merck and Baylor College of Medicine Advance Vaccine Development and Manufacturing for Neglected Dis en-cphi.cn
August 09, 2017
Collaboration furthers both parties' commitment to advance research and development for neglected diseases. Agreement focuses on optimizing vaccine process development and formulation and exchanging know-how
Merck scores expanded NICE recommendation in head, neck and oral cancer pharmafile
August 09, 2017
Merck has announced its approval of NICE’s decision to expand its recommendation of Erbitux (cetuximab) to include its use as a first-line treatment for recurrent or...
AstraZeneca, Merck in $8.5B Oncology Pact contractpharma
August 04, 2017
Will co-develop and co-commercialize Lynparza for multiple cancer types
Merck adds Chemical Products to Reaxys’ Chemistry Database pharmaasia
August 03, 2017
Allows customers to easily find, procure products in the Reaxys inventory and reduces barriers for customers to develop new chemistries, accelerating research.
Merck and AstraZeneca to develop and market lynparza for multiple cancer treatments pharmaceutical-technology
August 01, 2017
Merck has entered a global strategic oncology collaboration to jointly develop and commercialise AstraZeneca’s lynparza (olaparib) for the treatment of multiple cancer types.
AZ, Merck link to develop and commercialise cancer drugs pharmatimes
July 28, 2017
AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page